abstract |
Advantageous bispecific binding molecules are provided that include CD3 binding and CD33 binding moieties. The CD3 binding moiety comprises an antibody having a mutation in the Fc region with reduced binding to C1q and Fc gamma receptors. Bispecific binding molecules can be used in the treatment of cancer. |